drugset / Trial / NCT07486310

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

NCT07486310

Phase 2 Not yet recruiting 30 enrolled Guangdong Provincial People's Hospital
RandomizedFactorialOpen-labelTreatment

Summary

This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis. It aims to evaluate the safety and efficacy of systemic therapy plus Pressurized Intra-Peritoneal Aerosol Virus (PIPAV) with VRT106 compared to systemic therapy plus Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).

Timeline

Start
2026-03-01
Primary completion
2028-03-01
Completion
2029-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 1.5 mg/m2 Other
Subject VRT106 Unknown 9e+08 unknown Other

Indications